SPHRF Stock UPDATES Starpharma Holdings (SPHRF) 0.6610 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Starpharma Holdings (SPHRF) 0.6610 $SPHRF

FDA Grants Special Protocol Assessment (SPA) Agreement for Starpharma Phase 3 Recurrent BV Trial
Business Wire - Mon Jul 14, 4:35AM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel(R) bacterial vaginosis (BV) product for the prevention of recurrent BV.

New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.

The Ellen's Corkrum Recordings and Its Legal Implication [opinion]
by Dashward A. Wumah - All Africa Global Media - Fri Dec 20, 6:34AM CST
In the wake of Ellen Corkrum, former head of the Liberia Airport Authority, and her fiance Melvin Johnson, secret recordings of Musa Bility former Chairman of the Board of Directors of the Liberia Airport Authority (LAA), along with others accused by the Government of Liberia for Economic Sabotage in the tune of over US$1 million. (All Africa 2013), the secret recordings of Defense Minister, Brownie Samukai, and Mr. Chris Massaquoi, the Inspector General of the Liberia National Police

Research Report: Viral Conjunctivitis - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8l93r/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H2 2013" report to their offering. 'Viral Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Viral Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis. Scope - A snapshot of the global therapeutic scenario for Viral Conjunctivitis. - A review of the Viral Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Viral Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned NanoViricides, Inc. NovaBay Pharmaceuticals, Inc. Starpharma Holdings Limited Foresight Biotherapeutics, Inc. Redox Pharmaceutical Corporation For more information visit http://www.researchandmarkets.com/research/z8l93r/viral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Genital Herpes - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Genital Herpes
M2 - Tue Sep 03, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r3z3pp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Genital Herpes - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. Genital Herpes - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Genital Herpes. - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Genital Herpes pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AiCuris GmbH & Co. KG - Antigenics, Inc. - Flamel Technologies S.A. - Foamix Ltd. - NanoViricides, Inc. - Profectus BioSciences, Inc. - Starpharma Holdings Limited - Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/r3...tal_herpes About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Starpharma and Makhteshim Agan in Priostar Agrochemical Collaboration
PR Newswire - Wed Mar 13, 3:02AM CDT
Starpharma Holdings Ltd (ASX:SPL; OTCQX: SPHRY) and Makhteshim Agan Group today announced a collaboration program. This will see Starpharma's Priostar® dendrimer technology applied to novel crop protection formulations across Makhteshim Agan's extensive product portfolio.

Herpes Simplex Virus Treatment - Global Strategic Business Report
M2 - Thu Feb 14, 6:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fnf3m/herpes_simplex) has announced the addition of the "Herpes Simplex Virus Treatment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Herpes Simplex Virus Treatment in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Treatment Of Herpes Simplex Virus Infection 3. Hsv Vaccines - An Insight 4. Herpes Simplex Virus Infection - The Disease, Causes, Symptoms, And Diagnosis 5. Pipeline Analysis 6. Product Launche




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 112

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 164

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 175

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 120

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 129

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 16

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 83

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 69

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 197

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 228

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading

Top 5 Most Recently Viewed Articles

Microvast Welcomes New CFO Pat Schultz to Drive Growth

Updated Category News Views 460

Microvast Holdings, Inc. Welcomes Pat Schultz as Chief Financial Officer Microvast Holdings, Inc. (NASDAQ: MVST), a prominent name in advanced battery technologies, has announced a significant change in its executive leadership team. The company is excited to introduce Carl T “Pat” Schultz as its new Chief Financial Officer. Pat Schultz's Impressive Background With...

Continue Reading
Cipla Faces Lanreotide Shortage: UBS Maintains Buy Rating

Updated Category News Views 536

UBS Adjusts Cipla's Price Target Amid Lanreotide Challenges Recent developments have placed Cipla Ltd. (CIPLA:IN) in the spotlight as UBS has decided to maintain its Buy rating on the company's shares, albeit with a notable revision. The price target has been decreased from INR2,060.00 to INR1,960.00, reflecting anticipated challenges due to a shortage of Lanreotide, an...

Continue Reading
Innovative Strategies at GovFin 2025 for Financial Progress

Updated Category News Views 197

GovFin 2025: Shaping the Future of Financial Reporting GovFin 2025 brings together leading minds to discuss the transformation of municipal bond issuance and the Financial Data Transparency Act (FDTA). With nine agencies preparing to finalize the first phase of FDTA rulemaking, expectations are high. Each agency will devise proposals for their own data collection...

Continue Reading
Broadway Licensing Unveils Festive Musical Holiday Showcase

Updated Category News Views 166

Broadway Licensing Introduces a Joyous Holiday Production Broadway Licensing, the prominent musical imprint of Broadway Licensing Global, is thrilled to share the launch of its latest holiday musical, Christmas in Connecticut. This enchanting show brings to life the beloved 1945 Warner Bros. Pictures film through its contemporary adaptation. Overview of the Musical's...

Continue Reading
Innovative Quick Connect Device Revolutionizes Electrical Installations

Updated Category News Views 198

Innovative Electrical Fixture Quick Connect Device In a world where electrical installations can be complicated and time-consuming, one inventor has sought to simplify this process significantly. The Electrical Fixture Quick Connect Device is designed to transform how lighting fixtures are connected to electrical networks. The vision behind this invention is...

Continue Reading